Home>>Signaling Pathways>> Others>>Puromycin aminonucleoside

Puromycin aminonucleoside

Catalog No.GC10171

Puromycin aminonucleoside Chemical Structure

Aminonucleoside portion of the antibiotic puromycin

Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock
In stock
In stock

Customer Reviews

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:


Cell experiment [1]:

Cell lines

Madin-Darby canine kidney (MDCK) cells

Preparation method

The solubility of this compound in DMSO is >14.5mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

48 h


In vector- and PMAT-transfected MDCK cells, Puromycin aminonucleoside (PAN) exhibited cell cytotoxicity with the IC50 values of 48.9 ± 2.8 and 122.1 ± 14.5 μM, respectively. PAN (250 μM) was toxic to both PMAT-expressing and vector-transfected cells. Puromycin aminonucleoside uptake in PMAT-expressing cells was four fold higher at pH 6.6 than that at pH 7.4.

Animal experiment [2,3]:

Animal models

Nephrosis rats

Dosage form

Intravenous injection, 60 mg/kg, 150 mg/kg


In nephrosis rats, the number of podocytes per glomerulus was 90.7 on Day 4 in PAN (8 mg/100 g, i.v.) treated group. The amount of nephrin per glomerulus in PAN-treated nephrosis rats reduced to 0.46 ± 0.06 fmol and 0.35±0.04 fmol on Day 4 and Day 7. The nephrin amount per podocyte was significantly decreased association with the development of proteinuria in Puromycin aminonucleoside nephrosis rats. Rats given PAN (100 mg/kg, s.c.) gained less weight and their serum creatinine levels were higher than the control rats, indicating Puromycin aminonucleoside impaired renal function.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1]. Xia L, Zhou M, Kalhorn T F, et al. Podocyte-specific expression of organic cation transporter PMAT: implication in puromycin aminonucleoside nephrotoxicity. American Journal of Physiology-Renal Physiology, 2009, 296(6): F1307-F1313.

[2]. Kawakami, Hirotaka, et al. Dynamics of absolute amount of nephrin in a single podocyte in puromycin aminonucleoside nephrosis rats calculated by quantitative glomerular proteomics approach with selected reaction monitoring mode. Nephrology Dialysis Transplantation 27.4 (2011): 1324-1330.

[3]. Nosaka, Kazuo, et al. An adenosine deaminase inhibitor prevents puromycin aminonucleoside nephrotoxicity. Free Radical Biology and Medicine 22.4 (1997): 597-605.


IC50: N/A

Puromycin aminonucleoside, 3'-Amino-3'-deoxy-N6,N6-dimethyladenosine, is the aminonucleoside portion of the antibiotic puromycin. Puromycin aminonucleoside (PAN)-induced nephrosis in rats can provide a model for investigating the pathogenesis of severe proteinuric conditions.

In vitro: A pervious study used scanning (SEM) and transmission (TEM) electron microscopy to test the in vitro effects of PAN on rat glomerular podocytes. Slices of rat kidney were incubated with PAN. SEM analysis of glomeruli on kidney slices indicated incubation with PAN decreased the number of microvilli on podocyte cell bodies and increased the number of glomeruli. TEM morphometry showed PAN incubation significantly retarded the loss of podocyte foot processes that was observed in control groups [1].

In vivo: In Wistar rats, multiple injections of PAN resulted in sustained severe proteinuria and FSGHS lesions of their glomeruli. In PVG/c rats, a higher PAN dose was needed to induce chronic proteinuria. In acute PAN nephrosis induced by a single intravenous injection of PAN the mesangium of Wistar rats showed large amounts of lipid in contrast to a few small mesangial lipid droplets in nephrotic PVG/c rats. Moreover, after injection of colloidal carbon in nephrotic PVG/c rats no enhanced carbon accumulation was found in the mesangium when compared to nonproteinuric controls [2].

Clinical trial: N/A

[1] Grond J,Muller EW,van Goor H,Weening JJ,Elema JD.  Differences in puromycin aminonucleoside nephrosis in two rat strains. Kidney Int.1988 Feb;33(2):524-9.
[2] Bertram JF,Messina A,Ryan GB.  In vitro effects of puromycin aminonucleoside on the ultrastructure of rat glomerular podocytes. Cell Tissue Res.1990 May;260(3):555-63.

Chemical Properties

Cas No. 58-60-6 SDF
Synonyms 3'-Amino-3'-deoxy-N6,N6-dimethyladenosine
Chemical Name 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol
Canonical SMILES CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)N)O
Formula C12H18N6O3 M.Wt 294.31
Solubility ≥ 14.45 mg/mL in DMSO, ≥ 29.4 mg/mL in EtOH with gentle warming, ≥ 29.5 mg/mL in H2O with gentle warming Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Review for Puromycin aminonucleoside

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
4 Star
3 Star
2 Star
1 Star
Review for Puromycin aminonucleoside

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.